Drug Trial Radar · NCT06596252
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
308
Planned (sponsor's estimate)
Start
May 21, 2021
Primary completion
Dec 2026
Study completion Mar 2028
Sponsor
- Lead sponsor
- Dr. Falk Pharma GmbHIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
Conditions
- Eosinophilic Esophagitis
Interventions
BudesonideDrug
Twice daily intake of the tablet 30 min after a meal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients in histological remissionTime frame: 6 weeks
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Dr. Falk Investigational Site
Scottsdale, Arizona
Dr. Falk Investigational Site
Little Rock, Arkansas
Dr. Falk Investigational Site
La Jolla, California
Dr. Falk Investigational Site
San Diego, California
Dr. Falk Investigational Site
Doral, Florida
Dr. Falk Investigational Site
New Port Richey, Florida
Dr. Falk Investigational Site
Boise, Idaho
Dr. Falk Investigational Site
Boston, Massachusetts
Wyoming
Ann Arbor, Michigan
Dr. Falk Investigational Site
Wyoming, Michigan
Dr. Falk Investigational Site
Rochester, Minnesota
Dr. Falk Investigational Site
Freehold, New Jersey
Dr. Falk Investigational Site
New York, New York
Dr. Falk Investigational Site
Chapel Hill, North Carolina
Dr. Falk Investigational Site
Cleveland, Ohio
Dr. Falk Investigational Site
Mentor, Ohio
Wyoming
Philadelphia, Pennsylvania
Dr. Falk Investigational Site
Harlingen, Texas
Dr. Falk Investigational Site
Salt Lake City, Utah
Dr. Falk Investigational Site
Lynchburg, Virginia
Department of Gastroenterology, Hospital General de Tomelloso
Tomelloso, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.